NEW YORK – HTG Molecular Diagnostics reported after the close of the market on Wednesday an 11 percent year-over-year drop in its full-year revenues, driven by a significant decrease in collaboration revenue.
For the year ended Dec. 31, 2019, the Tucson, Arizona-based firm's revenues fell to $19.2 from $21.5 million in 2018, matching the Wall Street consensus estimate.